The ATTEMPT trial demonstrated that dapagliflozin adjunct to insulin reduced measured glomerular filtration rate (mGFR) in youth with type 1 diabetes, indicating reduction in renal hyperfiltration.
Dapagliflozin improved glycemic control, evidenced by decreased HbA1c and increased glucose time in range without increasing total daily insulin doses.
Body weight reduction was observed with dapagliflozin without significant adverse events; only one mild diabetic ketoacidosis (DKA) event occurred under ketone monitoring and education protocols.
Earlier trials with sotagliflozin and dapagliflozin in adults support renal and glycemic benefits of SGLT2 inhibitors, highlighting translational potential in youth with type 1 diabetes.
